Measles immunity among pregnant women aged 15–44 years in Namibia, 2008 and 2010

Cardemil, Cristina V.; Jonas, Anna; Beukes, Anita; Anderson, Raydel; Rota, Paul A.; Bankamp, Bettina; Gary, Howard E.; Sawadogo, Souleymane; Patel, Sadhna; Zeko, Sikota; Muroua, Clementine; Gaeb, Esegiel; Wannemuehler, Kathleen; Gerber, Sue; Goodson, James L.

doi:10.1016/j.ijid.2016.05.020

Cited by 8 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Women with unknown immune status could be offered the MMR vaccine as part of routine care of CHB patients prior to pregnancy if possible; however, very few cases have been reported of measles and rubella in Denmark in recent years (European CDC EC, 2017;WHO 2020a,b,c). In line with our study, reports from Asia and the Middle East showed seroprevalence estimates of antibodies against morbillivirus and rubella virus of approximately 90% (Almuneef et al 2006;Cardemil et al 2016), which is comparable to the Danish population.…”

Section: Measles Morbillivirus and Rubella Virussupporting

confidence: 91%

Prevalence of herpes -, measles morbillivirus-, parvovirus B19 - and rubella viruses immunoglobulin G among women with chronic hepatitis B of reproductive age in Denmark: A cross-sectional study

Bergløv

Hallager

Panum

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

The aim of this study was to investigate whether the seroprevalence of IgG antibodies against seven viruses (cytomegalovirus, herpes simplex virus 1&2, measles morbillivirus, parvovirus B19, rubella, and varicella-zoster virus), which can potentially compromise maternal and fetal wellbeing, differs based on country of origin among women with chronic hepatitis B (CHB). Method: This study was a single-center, hospital-based cross-sectional study. The study included women with CHB 15-45 years of age, included in the Danish Database for Hepatitis B and C. Seroprevalence estimates were calculated with a 95% confidence interval and were compared between age groups, regions of origin, and to the general population. Results: 177 women were included in the study. Overall, the seroprevalences of antibodies were similar among women with CHB with origin outside Denmark and compared to the general population in Denmark, but there was a notable difference in the seroprevalence of antibodies against herpes simplex 2 between women from Africa (37.1% CI 95% 22.0;55.1) and women from the Middle East (2.5% CI 95% 0.1;14.7). Conclusion: Women with CHB whose origin is outside Denmark do not appear to differ, based on origin, or be at greater risk of acquiring these viruses during pregnancy than their Danish counterparts.

show abstract

Section: Measles Morbillivirus and Rubella Virussupporting

confidence: 91%

Prevalence of herpes -, measles morbillivirus-, parvovirus B19 - and rubella viruses immunoglobulin G among women with chronic hepatitis B of reproductive age in Denmark: A cross-sectional study

Bergløv

Hallager

Panum

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Seventy-one studies fulfilled the eligibility criteria (Supplementary data 4). Twenty-eight studies reported on safety [24], [25], [29], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61] and 62 reported on immunogenicity [23], [24], [25], [29], [30], [33], [34], [35], [36], [37], [39], [40], [41], [43], [44], [45], [47], [48], [50], [51], [53], [55], [56], [57], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], …”

Section: Resultsmentioning

confidence: 99%

Safety and Immunogenicity of Measles Vaccination in HIV-Infected and HIV-Exposed Uninfected Children: A Systematic Review and Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

Background HIV-infected and HIV-exposed uninfected (HEU) children have an increased risk of measles that may be due to altered immune responses or suboptimal timing of measles vaccination. We aimed to evaluate the safety and immunogenicity of measles vaccination in HIV-infected and HEU children. Methods For this systematic review and meta-analysis, we searched PubMed, Embase, Cochrane Library, CINAHL, Global Health Library and IndMED on May 9, 2018. Studies were included if they reported on safety or seroresponse (either seroprotection/seropositivity/seroconversion) after measles vaccination in HIV-infected or HEU children. We calculated pooled estimates to compare immunogenicity outcomes between HIV-infected, HEU and HIV-unexposed children, using risk ratios [RRs] (with 95%CIs). PROSPERO registration number: CRD42017057411. Findings Seventy-one studies met the inclusion criteria (15,363 children). Twenty-eight studies reported on safety; vaccine-associated adverse events and deaths were uncommon. Sixty-two studies reported on immunogenicity, 27 were included in the meta-analysis. HIV-infected children had lower seroresponse rates after primary vaccination compared with HIV-unexposed (RR 0.74; 95%CI: 0.61–0.90, I 2 = 85.9%) and HEU children (0.78; 0.69–0.88, I 2 = 77.1%), which was mitigated by antiretroviral therapy and time interval between vaccination and serology. HEU and HIV-unexposed children had similar seroresponses. Vaccination at 6-months resulted in similar proportions of HIV-infected children having seroresponse compared with HIV-unexposed (0.96; 0.77–1.19) and HEU children (1.00; 0.73–1.37, I 2 = 63.7%). Interpretation Primary measles vaccination at 6-months of age may provide protection against measles during early infancy in settings with high prevalence of maternal HIV-infection, however, further studies are needed to evaluate this strategy in HEU children and HIV-infected children receiving antiretroviral therapy. Funding South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation in Vaccine Preventable Diseases; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit.

show abstract

“…In our study, measles seropositivity increased as the number of pregnancies increased in single analyses, but this difference was not detected in further analyzes. Women who had two pregnancies had a 1.64 times higher measles seropositivity than those who had one pregnancy ( P =0.016) ( 6 ). Measles seronegativity was unrelated to the number of births in women ( P >0.05) ( 32 ).…”

Section: Discussionmentioning

confidence: 99%

Measles Seroprevalence and Related Factors in Women Aged 15-49 Years Old, in Mersin, Turkey

Yalcın¹,

Sasmaz²

2023

ijph

View full text Add to dashboard Cite

Background: If the mother is immune to measles, the infant is protected against measles infection after birth with maternal immunity. Therefore, the mother's immunity to measles is the most important factor in protecting the baby from measles in the first year. This study aimed to investigate measles seroprevalence and related factors in women between Oct 2019 and Jun 2021. Methods: The cross-sectional study was conducted on women aged 15-49 yr in Mersin city. Overall, 400 people were included in the study. NovaLisa Measles IgG ELISA (NovaTec Immunodiagnostica GmbH®) kit was used to measure measles IgG antibodies in serological analyses. The research was conducted between Oct 2019 and Jun 2021. In the analysis of the data; descriptive statistics, chi-square analysis, and binary logistic regression analysis were used. The statistical significance level was accepted as P≤0.05. Results: Measles seropositivity was detected in 103 (25.7%) of the women. This rate was found 5.5% in the 15-19 yr age group, 20.0% in the 20-24 yr age group, 14.5% in the 25-29 yr age group, 23.0% in the 30-34 yr age group, 42.3% in the 35-39 yr age group, 42.3% in the 40-44 yr age group and 37.5% in the 45-49 yr age group. In the logistic regression analysis, the rate of seropositivity was compared to those in the 15-19 yr age group; it was found to be 4.33 times (P=0.03) at the age of 20-24 yr, 12.71 times (P<0.001) at the age of 40-44 yr, and 10.40 times (P<0.001) at the age of 45-49. Conclusion: Three out of every four babies born in our region are not adequately protected against measles.

show abstract

Measles immunity among pregnant women aged 15–44 years in Namibia, 2008 and 2010

Abstract: Late in a large measles outbreak, 13% of pregnant women in Namibia, and almost one in four 15-19-year-old pregnant women, remained susceptible to measles. In Namibia, immunization campaigns with measles-containing vaccine should be considered for adults.

Cited by 8 publications

References 20 publications

Prevalence of herpes -, measles morbillivirus-, parvovirus B19 - and rubella viruses immunoglobulin G among women with chronic hepatitis B of reproductive age in Denmark: A cross-sectional study

Prevalence of herpes -, measles morbillivirus-, parvovirus B19 - and rubella viruses immunoglobulin G among women with chronic hepatitis B of reproductive age in Denmark: A cross-sectional study

Safety and Immunogenicity of Measles Vaccination in HIV-Infected and HIV-Exposed Uninfected Children: A Systematic Review and Meta-Analysis

Measles Seroprevalence and Related Factors in Women Aged 15-49 Years Old, in Mersin, Turkey

Contact Info

Product

Resources

About